Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VivoSim LabsFRA:4OR 33 3-Year EPS without NRI Growth Rate is 39.10% as of Mar. 2026, which is 145% above its 10-year median of 15.95. GuruFocus rates FRA:4OR with a GF Score™ of 33/100 and a GF Value™ of €16.12. The stock has 6 warning signs investors should review. Among 1,167 Biotechnology companies, VivoSim Labs ranks better than 76.18% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 39.10% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 27.20% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 25.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of VivoSim Labs was 39.10% per year. The lowest was -533.40% per year. And the median was 15.95% per year.
VivoSim Labs (FRA:4OR) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
VivoSim Labs 3-Year EPS without NRI Growth Rate Related Terms
FRA:4OR vs SLXN, CDT, CLDI: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, VivoSim Labs's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's 3-Year EPS without NRI Growth Rate falls into.
VivoSim Labs 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 39.10% mean?
VivoSim Labs (FRA:4OR) has a 3-Year EPS without NRI Growth Rate of 39.10% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for VivoSim Labs and its competitors. This is 145% above median its historical median of 15.95. According to the industry distribution chart, VivoSim Labs ranks #278 out of 1167 companies in the Biotechnology industry, placing it in the top 23.8%.
Is VivoSim Labs' 3-Year EPS without NRI Growth Rate too high?
VivoSim Labs' current 3-Year EPS without NRI Growth Rate of 39.10% is 145% above median its 10-year median of 15.95. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.60. VivoSim Labs' value of 39.10% is 135.5% above this industry median. Based on the distribution chart, VivoSim Labs ranks #278 out of 1167 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, VivoSim Labs has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' 3-Year EPS without NRI Growth Rate compare to SLXN and CDT?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #278 out of 1167 companies for 3-Year EPS without NRI Growth Rate. This places VivoSim Labs in the top 24% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 16.60. VivoSim Labs' value of 39.10% is 135.5% above this benchmark. While the company's 10-year median is 15.95 vs. the industry median of 16.60, VivoSim Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.60, based on 1,167 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VivoSim Labs's current 3-Year EPS without NRI Growth Rate of 39.10% is 135.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for VivoSim Labs and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VivoSim Labs's current 3-Year EPS without NRI Growth Rate is 39.10%, which is 145% above median its own 10-year median of 15.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current 3-Year EPS without NRI Growth Rate of 39.10%. The stock's GF Value™ is €16.12, compared to a current price of €3.49 — trading 78.3% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 39.10%, which is 145% above median its 10-year median of 15.95 and 135.5% above the Biotechnology industry median of 16.60. VivoSim Labs' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current 3-Year EPS without NRI Growth Rate is 39.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 78.3% below its estimated GF Value™ of €16.12.
Key valuation signals for FRA:4OR:
3-Year EPS without NRI Growth Rate: 39.10% (145% above median its 10-year median of 15.95)
GF Value™: €16.12 vs. price of €3.49 (78.3% below fair value)
Industry Position: 135.5% above the Biotechnology median (#278 of 1167)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
33GF Score
Get the complete analysis for FRA:4OR
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
